Abstract
Introduction: The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analy......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
